Budure Alexandra Nicoleta, Winquist Eric, Palma David, Correa Rohann Jonathan Mark
Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
London Health Sciences Centre, London, Ontario, Canada.
BMJ Case Rep. 2019 Jul 15;12(7):e228956. doi: 10.1136/bcr-2018-228956.
Herein we present a case of a patient with Charcot-Marie-Tooth (CMT) disease who was diagnosed with locally invasive nasopharyngeal carcinoma. In the context of CMT, the use of standard platinum-based radio-sensitising chemotherapy would have been neurotoxic and is contraindicated in patients with CMT. However, no alternate antineoplastic treatment strategies for patients with CMT have been described in the literature. In this case, an innovative approach was taken using radical radiotherapy concurrently with the biological agent cetuximab. The patient did not suffer any neurotoxicity, though he did experience several expected toxicities commonly associated with this regimen. The patient nonetheless completed treatment and has experienced an excellent response both clinically and radiographically and remains disease free.
在此,我们报告一例患有夏科-马里-图斯(CMT)病的患者,该患者被诊断为局部侵袭性鼻咽癌。在CMT的情况下,使用标准的铂类放射增敏化疗会具有神经毒性,CMT患者禁用。然而,文献中尚未描述针对CMT患者的替代抗肿瘤治疗策略。在本病例中,采用了一种创新方法,即根治性放疗联合生物制剂西妥昔单抗。该患者未出现任何神经毒性,尽管他确实经历了与该治疗方案相关的几种预期毒性。尽管如此,患者完成了治疗,在临床和影像学上均有出色反应,且仍无疾病。